j-2

HSP27 inhibitor J2 (J2) (J2) is a HSP27 inhibitor, inhibits a production of HSP27 giant polymers, thereby having an effect of inhibiting a chaperone function of the HSP27 and reducing a cell protection function.

JNJ-20788560 is a delta opioid receptor (DOR) agonist with analgesic activity. It is more selective for DOR than for mu opioid receptors (MOR).

JNJ-26489112 is a CNS-active agent and inhibitor of voltage-gated Na+ channels and N-type Ca2+ channels with broad-spectrum anticonvulsant activity in rodents and can be used to study neurological disorders.

2-Deacetoxydecinnamoyltaxinine J is a natural product from Taxus cuspidta Sibe et Zucc.

2-Deacetoxytaxinine J shows significant in vitro activity against breast cancer cell line at a concentration of 20 microM and 10 microM in MCF-7 and MDA-MB-231 respectively.

The ED50 of J-2156 in rats for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws was 3.7 and 8.0 mg kg, respectively. J-2156 is a high potent, selective somatostatin receptor type 4 (SST4 receptor) agonist with IC5

LJ-2698 is an adenosine A3 receptor antagonist under investigation for treating emphysema and DKD (Diabetic Kidney Disease). In mouse lung models, LJ-2698 effectively mitigates elastase-induced adverse effects and inhibits matrix metalloproteinase activity and apoptosis. Additionally, it is being explored for its potential in treating diabetic nephropathy, successfully preventing various types of kidney damage in mice.

JNJ-2901 is an inhibitor of M. tuberculosis cytochrome bc1:aa3. It effectively reduces bacterial load in acute and chronic mouse infection models of M. tuberculosis H37Rv-ΔcydAB. JNJ-2901 is useful for tuberculosis (TB) research.

DNJ-20 is an α-glucosidase inhibitor with an IC50 of 55.3 μg/mL. It exhibits broad-spectrum activity against SARS-CoV-2. By interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), DNJ-20 hinders the proper processing of viral glycoproteins, thus blocking the formation and infection of viral particles. It is effective against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43, with IC50 values reaching up to 1.49 μM. DNJ-20 can be utilized for pan-coronavirus research.

JNJ-28312141 is an orally active CSF1R inhibitor and a FLT3 inhibitor. JNJ-28312141 is a new agent with potential therapeutic activity in acute myeloid leukemia and in settings where CSF-1-dependent macrophages and osteoclasts contribute to tumor growth a

JNJ-28330835 is a selective androgen receptor modulator with minimal prostate hypertrophic activity.

JNJ-28610244 is a specific agonist of the H4 receptor. It acts by blocking Mac-1-dependent activation of p38 MAPK.

ZYJ-25e is an oral histone deacetylase inhibitor (HDACi) with potent antitumor activities.

JNJ-2408068 is an inhibitor of respiratory syncytial virus (RSV). JNJ-2408068 exhibited potent antiviral activity with EC50 of 2.1 nM. A similar inhibitory effect was observed in a RSV-mediated cell fusion assay (EC50= 0.9 nM). JNJ-2408068 interferes with

JNJ-26070109, an antagonist of cholecystokinin CCK2 receptor, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat.

JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy.

JNJ-26146900 is a nonsteroidal androgen receptor (AR) ligand with tissue-selective activity in rats. JNJ-26146900 binds to the rat AR with a K(i) of 400nM.

JNJ-26990990 is a broad-spectrum anticonvulsant drug and a second-generation follow-up to the marketed drug topiramate. It offers the same anticonvulsant effects as topiramate but without the side effects associated with topiramate's carbonic anhydrase inhibition. Additionally, JNJ-26990990 has potential use in treating inflammatory pain, neuropathic pain, and depression. [It] entered phase II clinical trials in October 2007.

JNJ-27141491 is a potent, noncompetitive antagonist of human CCR2.

JNJ-28583867 is an inhibitor of histamine H(3) receptor antagonist and serotonin reuptake.

JNJ-27390467 is a bioactive chemical.

CJ-2360 is a potent, orally active ALK inhibitor, capable of acting on wild-type ALK (IC50: 2.2 nM) and F1197M (IC50: 4.0 nM), G1269A (IC50: 8.8 nM), L1196M (IC50: 6.3 nM) and S1206Y ALK mutant (IC50: 8.9 nM). CJ-2360 strongly inhibited two clinically reported ALK mutants (C1156Y and L1196M) and 468 kinases (LTK, MERTK, CLK1, DAPK1, and DAPK2).

J-2156 TFA is a selective and potent growth inhibitor receptor type 4 (SST4) agonist that acts on the human SST4 receptor (IC50: 0.05 nM) and rat SST4 receptor (IC50: 0.07 nM). J-2156 TFA exhibited anti-inflammatory activity and was able to alleviate mechanical abnormal pain and mechanical hyperalgesia in the rat ipsilateral hind paw.

JNJ-26993135 is a potent and selective leukotriene A4 hydrolase (LTA4H) inhibitor.